Key Highlights
- UNCY was down 9.09 percent at USD 3.40 in pre-market trading on November 2, 2026.
- The FDA accepted the resubmitted oxylanthanum carbonate application, with a PDUFA date of March 25, 2027.
- The resubmission was filed on September 29, 2026.
- Second-quarter 2026 results were released on August 12, 2026.
- Securities class action notices about the company circulated on October 29 and 30, 2026.
What moved the stock in pre-market trading
Unicycive Therapeutics (NASDAQ:UNCY) was down 9.09 percent at USD 3.40 in pre-market trading on November 2, 2026. No company announcement dated November 2, 2026 was identified.
The pullback follows a stretch of regulatory news and law firm notices about a securities class action, which may be weighing on sentiment.
Low-priced biotech shares often move sharply on thin pre-market volume, so the early print may not reflect where the stock settles once the regular session begins.
The FDA resubmission in detail
According to a company press release dated October 21, 2026, the FDA accepted the resubmitted New Drug Application for oxylanthanum carbonate, known as OLC, and set a PDUFA goal date of March 25, 2027. The company had resubmitted the application on September 29, 2026.
A PDUFA date is the target date for the agency to complete its review. It does not guarantee approval, and the outcome could go either way. Investors typically watch the review period for any request for additional information or inspection findings, which the company would be expected to disclose.
Business background and recent results
Unicycive is a clinical-stage biotechnology company developing treatments for kidney disease. OLC is intended to control high phosphate levels in patients on dialysis.
The company announced the appointment of Meredith Manning to its Board of Directors on October 1, 2026. It last reported quarterly results on August 12, 2026, and no financial results dated October or November 2026 were identified.
Balance sheet and risks
Notices published on October 29 and October 30, 2026 told investors with losses about a deadline to seek a lead role in a securities class action against the company. The notices are allegations, and the company has not been reported to have lost any case.
As a penny stock, UNCY can be volatile and may trade thinly, and a clinical-stage firm without product Revenue may need further capital, which can dilute shareholders. No new financing announcement dated October or November 2026 was found.
What to watch next
The next milestones are the March 25, 2027 PDUFA date, any labeling or inspection updates ahead of it, and the third-quarter 2026 financial report with its cash position.
Developments in the class action could also shape sentiment before the regulatory decision. Any commentary on launch preparation, Manufacturing readiness or commercial partnerships would add context to the March 2027 timeline.






Please wait processing your request...